newsfilter
← Latest News
PR Newswire·

IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026

  • IceCure Medical (NASDAQ: ICCM) will release financial & operational results for the nine months ended September 30, 2026, before the Nasdaq open on November 18, 2026.
  • The company will host a conference call & webcast at 10:00 a.m. EST on November 18, 2026, with dial-in numbers for US & international participants.
  • A live webcast is available at the provided Veidan link, with a recording accessible via the company's investor relations site.
  • IceCure develops liquid-nitrogen-based cryoablation systems for tumors in breast, kidney, bone, & lung cancer, with its ProSense® system marketed globally.
  • ProSense® is the first-and-only FDA-cleared device for treating low-risk breast tumors ≤1.5 cm in patients aged 70+ receiving adjuvant endocrine therapy.
  • The press release includes forward-looking statements regarding expected results & conference calls, noting risks such as funding, regulatory changes, & Middle East instability.
  • Meir Peleg, CFO, is listed as the IR contact for inquiries.
Company
IceCure Medical
Keywords
IceCure Medical